| Symbol | IMNN |
|---|---|
| Name | IMUNON, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 997 LENOX DRIVE,SUITE 100, LAWRENCEVILLE, New Jersey, 08648, United States |
| Telephone | +1 -609 896-9100 |
| Fax | — |
| — | |
| Website | https://www.imunon.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0000749647 |
| Description | Imunon Inc is developing new medicines that harness the building blocks of life to work in harmony with the bodys immune system. It is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. Additional info from NASDAQ: |
New Form SCHEDULE 13G/A - Imunon, Inc. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001172661-26-002157 <b>Size:</b> 10 KB
Read more(90% Positive) IMUNON, INC. (IMNN) Announces Enrollment Update for community Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment
Read moreNew Form ARS - Imunon, Inc. <b>Filed:</b> 2026-05-04 <b>AccNo:</b> 0001493152-26-021118 <b>Size:</b> 1 MB
Read moreNew Form DEF 14A - Imunon, Inc. <b>Filed:</b> 2026-05-04 <b>AccNo:</b> 0001493152-26-020999 <b>Size:</b> 3 MB
Read more(90% Positive) IMUNON, INC. (IMNN) Announces Enrollment Update for trial Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment
Read moreIMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study
Read moreNew Form 10-K - Imunon, Inc. <b>Filed:</b> 2026-03-31 <b>AccNo:</b> 0001493152-26-013850 <b>Size:</b> 7 MB
Read moreIMUNON Reports Updated Phase 2 Data Showing Continued Improvement in Median Overall Survival with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian Cancer
Read moreIMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026
Read more